Understanding Fatigue in Multiple Sclerosis and Monoaminergic Circuits

Clinicians recognize fatigue in multiple sclerosis as one of the most pervasive, disabling symptoms reported by patients globally. Although demyelinating lesions and axonal transection characterize disease pathology, conventional structural neuroimaging markers correlate poorly with subjective exhaustion. Consequently, neuroscientists have increasingly turned to advanced functional neuroimaging to elucidate underlying central mechanisms. In particular, monoaminergic neurotransmitters play critical regulatory roles in maintaining central arousal, sustained attention, reward processing, and neuroimmune equilibrium. Serotonergic, dopaminergic, and noradrenergic projections extend broadly across cerebral cortices and deep subcortical nuclei. Therefore, when pathological neuroinflammatory processes disrupt these ascending circuits, patients frequently experience profound physical and cognitive exhaustion. Furthermore, chronic central inflammation alters neurotransmitter synthesis and receptor availability, directly aggravating fatigue severity. While earlier research primarily examined static regional tissue damage, modern neuroimaging highlights dynamic communication across distributed neural networks. Understanding how monoaminergic circuits reconfigure over time provides vital clues regarding why conventional therapies often fail to relieve this symptom. Thus, investigating dynamic monoaminergic functional architecture represents an essential frontier in contemporary neurology. Ultimately, resolving these complex network interactions can help clinicians identify objective physiological targets for future therapeutic discovery.

Mapping Neurotransmitter Pathways via Receptor Density Atlases

To determine the biological basis of fatigue, recent investigations have paired functional neuroimaging with molecular positron emission tomography atlases. Specifically, researchers evaluated 217 individuals with multiple sclerosis alongside 60 healthy controls in an extensive neuroimaging cohort. The investigators measured participant fatigue using the Fatigue Scale for Motor and Cognitive Functions to categorize patient symptom severity. Additionally, the team integrated high-resolution normative PET atlases for multiple monoaminergic receptors and transporters. These targets included serotonin 5-HT1A and 5-HT2A receptors, dopamine D1 and D2 receptors, alongside serotonin, dopamine, and noradrenaline transporters. By overlaying resting-state fMRI data onto these molecular density distributions, investigators defined circuit-specific connectivity profiles for each neurotransmitter system. Moreover, this spatial mapping permitted researchers to allocate individual cortical regions to canonical resting-state networks. Consequently, the multimodal methodology bridged macroscopic network dynamics with microscopic neurochemical architecture in an unprecedented manner. This innovative paradigm allows clinicians to observe how specific neurotransmitter deficits reshape large-scale neural interactions in real time. Therefore, combining connectomics with molecular imaging provides an unprecedented framework for dissecting neuropsychiatric symptoms in demyelinating disorders. Furthermore, this strategy establishes a reproducible benchmark for future neuroimaging investigations into brain connectivity changes.

Static Versus Dynamic Network Functional Connectivity

Traditional functional neuroimaging studies predominantly evaluate static connectivity, which averages signal correlations across an entire scanning session. However, the human brain constantly reorganizes its functional connections to adapt to continuous cognitive demands. Dynamic functional connectivity captures these rapid temporal reconfigurations, offering deeper insight into neural network flexibility. In graph theoretical analysis, researchers track how brain regions transition between distinct functional communities over time. Specifically, network flexibility quantifies the frequency with which a brain region switches its network allegiance. In contrast, network promiscuity measures the total number of distinct networks that a region interacts with during the recording period. When monoaminergic modulation functions normally, it preserves an optimal balance between regional stability and dynamic adaptability across networks. Therefore, any disruption in dynamic switching impairs cognitive efficiency and accelerates executive exhaustion. Furthermore, dynamic connectivity metrics show superior sensitivity over static measures when evaluating subjective neurological symptoms like fatigue. By tracking temporal transitions within monoaminergic circuits, researchers can uncover functional instability that static analyses completely miss. Consequently, dynamic graph metrics offer an indispensable method to capture subtle alterations in brain communication.

Key Neuroimaging Findings and Dynamic Circuit Reconfiguration

The clinical findings revealed striking differences in circuit dynamics between fatigued patients, non-fatigued patients, and healthy individuals. Notably, people with multiple sclerosis who experienced significant fatigue exhibited altered flexibility and promiscuity within specific monoaminergic circuits. Serotonergic and dopaminergic pathways showed markedly abnormal switching rates between frontoparietal, salience, and default mode networks. In addition, patients experiencing severe fatigue displayed excessive, non-productive network promiscuity in subcortical dopamine circuits. This pathological hyper-promiscuity suggests that brain regions make erratic, inefficient functional connections instead of maintaining stable communication pathways. Conversely, patients without fatigue demonstrated dynamic switching patterns that closely resembled healthy control profiles. Furthermore, researchers detected a direct correlation between aberrant dynamic switching and worse cognitive fatigue scores on clinical assessments. Importantly, these dynamic functional alterations remained significant even after controlling for total white matter lesion load and physical disability. Thus, monoaminergic network instability serves as an independent driver of subjective fatigue, rather than merely reflecting overall structural disease burden. Moreover, these quantifiable dynamic changes highlight the vulnerability of monoaminergic hubs under conditions of continuous neuroinflammatory stress. Accordingly, these neuroimaging signatures establish a direct link between monoaminergic dysfunction and clinical symptom manifestation.

Translational Implications for Clinical Neurotherapeutics

These neuroimaging discoveries provide substantial opportunities for developing individualized therapeutic strategies in neuroimmunology. Currently, standard clinical management of fatigue relies on generic lifestyle interventions and empirical pharmacotherapy, which often produce suboptimal results. However, identifying specific circuit disruptions enables clinicians to select targeted pharmacological agents with greater precision. For instance, patients demonstrating prominent dopamine circuit instability may benefit preferentially from wakefulness-promoting agents, amantadine, or specific dopamine agonists. Similarly, patients exhibiting primary serotonergic or noradrenergic dysregulation might respond better to dual reuptake inhibitors. Additionally, these dynamic connectivity markers could serve as sensitive endpoints for evaluating novel disease-modifying therapies in clinical trials. Beyond pharmacotherapy, non-invasive neuromodulation techniques such as repetitive transcranial magnetic stimulation can target nodes within aberrant circuits. Consequently, clinicians can utilize dynamic connectivity atlases to personalize coil placement and stimulation parameters effectively. Therefore, bridging molecular imaging with functional connectomics transforms our diagnostic approach, guiding neurologists toward precision medicine for fatigue management. In summary, these insights establish a compelling foundation for innovative multimodal treatment algorithms in clinical neuroimmunology.

Frequently Asked Questions

How does monoaminergic dysregulation contribute to MS fatigue?

Monoaminergic neurotransmitter pathways, including dopamine, serotonin, and noradrenaline, modulate central arousal, mood, and effort valuation. Consequently, structural or functional disruption within these pathways impairs dynamic signal coordination across major brain networks. This breakdown elevates the perceived mental effort needed for daily cognitive tasks, ultimately producing severe central fatigue.

Can conventional structural brain MRI explain subjective fatigue in MS?

Conventional structural MRI reliably quantifies white matter lesion volume and cerebral atrophy. However, these static volumetric metrics correlate weakly with subjective fatigue scores. Conversely, time-varying functional neuroimaging and receptor-informed connectomics capture dynamic disruptions in communication efficiency across neural networks, thereby providing far superior sensitivity for evaluating subjective central fatigue symptoms.

What therapeutic possibilities emerge from monoaminergic circuit research?

Identifying precise monoaminergic connectivity alterations enables clinicians to design more targeted interventions. Specifically, future treatment strategies may combine selective pharmacological agents, such as dopaminergic stimulants or noradrenergic reuptake inhibitors, with non-invasive neuromodulation techniques like transcranial magnetic stimulation. Consequently, these tailored regimens could normalize dynamic circuit flexibility and alleviate debilitating symptoms.

Disclaimer: This content is for informational and educational purposes only and should not be considered medical advice. Always consult a qualified healthcare provider for diagnosis and treatment. Refer to the latest local and national guidelines for clinical practice.

References

1. Bet MDA et al. Functional connectivity dynamics of monoaminergic circuits related to fatigue in multiple sclerosis. J Neurol. 2026 Jun 02. doi: 10.1007/s00415-026-13876-0. PMID: 42228097.


2. Hechenberger SMC, Broeders TAA, Bet MDA, et al. Time-varying brain functional reconfiguration patterns associated with fatigue in multiple sclerosis. Hum Brain Mapp. 2026;47(4):e26650.


3. Dobryakova E, Genova HM, DeLuca J, Wylie GR. The dopamine imbalance hypothesis of fatigue in multiple sclerosis and other neurological disorders. Front Neurol. 2015;6:52.